NASDAQ : ALXO
ALX Oncology Holdings Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 168.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 168.70M |
| Enterprise Value | 41.51M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 138.28M |
| Shares Outstanding | 138.28M |
| Shares Change (YoY) | +61.42% |
| Shares Change (QoQ) | +29.71% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 58.49% |
| Float | 94.96M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.24 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.71 |
| Quick Ratio | 9.43 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.84 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -80.65% |
| Return on Assets (ROA) | -40.40% |
| Return on Invested Capital (ROIC) | -45.42% |
| Return on Capital Employed (ROCE) | -56.69% |
| Weighted Average Cost of Capital (WACC) | 7.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.69M |
| Employee Count | 48 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -23.27% |
| 50-Day Moving Average | 1.51 |
| 200-Day Moving Average | 1.82 |
| Relative Strength Index (RSI) | 47.41 |
| Average Volume (20 Days) | 1,515,488 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.98M |
| Short Previous Month | 5.67M |
| Short % of Shares Out | 4.32% |
| Short % of Float | 6.29% |
| Short Ratio (days to cover) | 3.83 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -82.79M |
| Pretax Income | -80.89M |
| Net Income | -80.89M |
| EBITDA | -82.30M |
| EBIT | -82.79M |
| Earnings Per Share (EPS) | -$0.93 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 138.23M |
| Total Debt | 11.04M |
| Net Cash | 127.19M |
| Net Cash Per Share | $0.92 |
| Equity (Book Value) | 136.19M |
| Book Value Per Share | 0.99 |
| Working Capital | 128.68M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -70.78M |
| Capital Expenditures | -172,000 |
| Depreciation & Amortization | 495,000 |
| Net Borrowing | 6.03M |
| Free Cash Flow | -70.95M |
| FCF Per Share | -$0.51 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -61.42% |
| Shareholder Yield | n/a |
| Earnings Yield | -76.48% |
| FCF Yield | -42.06% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.60 |
| Price Target Difference | 277.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |